A novel small molecule phagocytosis inhibitor, <scp>KB</scp>‐208, ameliorates <scp>ITP</scp> in mouse models with similar efficacy as <scp>IVIG</scp>
KB-208 is similar to IVIG for the amelioration of ITP in multiple mouse strains. Chronic administration of KB-208 for 60 days did not demonstrate in vivo toxicity. These findings indicate that KB-208 is efficacious, without significant in vivo toxicities in mice, and is a potential small molecule candidate for further evaluation to be used in the treatment of ITP and possibly all immune cytopenias where phagocytosis is responsible for the pathophysiology.
Authors
- Beth Binnington
- Melissa M. Lewis‐Bakker
- Melika Loriamini
- Donald R. Branch (ORCID: https://orcid.org/0000-0002-8974-2451)
- Lakshmi P. Kotra (ORCID: https://orcid.org/0000-0002-7071-4637)
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Krembil Research Institute
- Canadian Blood Services (CA)
Publication Details
- Journal
- Transfusion
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1111/trf.18060
- Citations
- 2
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Canadian Blood Services